Home Newsfeeds FTC To Challenge Intercontinental Exchange Takeover Of Black Knight

FTC To Challenge Intercontinental Exchange Takeover Of Black Knight

-Bloomberg

byBenzinga Newsdesk

February 27, 2023

1 minute read

-Bloomberg

RBC Capital Downgrades Rackspace Tech to Sector Perform, Lowers Price Target to $7

By Benzinga Newsdesk

August 11, 5:08 AM

RBC Capital analyst Daniel Perlin downgrades Rackspace Tech (NASDAQ:RXT) from Outperform to Sector Perform and lowers the price target from $9 to $7.

RXT

Mizuho Maintains Buy on NIO, Lowers Price Target to $42

By Benzinga Newsdesk

September 8, 6:55 AM

Mizuho analyst Vijay Rakesh maintains NIO (NYSE:NIO) with a Buy and lowers the price target from $48 to $42.

NIO

News

Ebix Says Has Received ‘inbound interest from several reputed strategic and institutional international players, for substantial investments in Ebix or/and its subsidiaries,’ Strategic Investment Committee Will Be Evaluating Any Such Offers

By Bill Haddad

October 21, 8:28 AM

Strategic Investment Committee – The Company announced that it has received inbound interest from several reputed strategic and institutional international players, for substantial investments in Ebix or/and its

EBIX

Better Therapeutics Completes Exploratory Trial For Fatty Liver Disease And Announces Topline Results; Co. Reports ‘Study Conducted with Arizona Liver Health Met Primary Endpoint’

By Benzinga Newsdesk

December 8, 8:04 AM

Study Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients Company Intends to Apply

BTTX

FTC To Challenge Intercontinental Exchange Takeover Of Black Knight

Related Posts

RBC Capital Downgrades Rackspace Tech to Sector Perform, Lowers Price Target to $7

Mizuho Maintains Buy on NIO, Lowers Price Target to $42

Ebix Says Has Received ‘inbound interest from several reputed strategic and institutional international players, for substantial investments in Ebix or/and its subsidiaries,’ Strategic Investment Committee Will Be Evaluating Any Such Offers

Better Therapeutics Completes Exploratory Trial For Fatty Liver Disease And Announces Topline Results; Co. Reports ‘Study Conducted with Arizona Liver Health Met Primary Endpoint’